Trials / Unknown
UnknownNCT04520295
ctDNA Screening in Advanced HER2 Positive Gastric Cancer
Predictive Biomarkers Screening by ctDNA Detection in Advanced HER2 Positive Gastric Cancer Patients Treated by Trastuzumab Plus Chemotherapy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Ruijin Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To identify molecular biomarker panel correlating with efficacy of trastuzuamb in advanced HER2 positive gastric cancer patients. To observe the molecular evolution of HER2 positive gastric cancer during treatment by ctDNA detection.
Detailed description
Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | ctDNA screening | Molecular events including gene mutation, fusion and amplification will be detected by next generation sequencing platform (OncoScreen Plus panelTM) using ctDNA collected from peripheral blood samples of gastric cancer patients. For HER2 positive patients, samples will be collected at baseline, first surveillance after treatment and disease progression. For HER2 negative patients, samples will be collected at baseline as negative control. |
Timeline
- Start date
- 2020-05-19
- Primary completion
- 2023-05-31
- Completion
- 2025-05-31
- First posted
- 2020-08-20
- Last updated
- 2020-08-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04520295. Inclusion in this directory is not an endorsement.